Vistella

Vistella Therapeutics is a pre-clinical stage biotechnology company dedicated to discovering and developing novel small molecule therapeutics for neurodegenerative diseases. The company's approach centers on targeting the structural biology of protein misfolding, particularly amyloid-beta and tau proteins associated with Alzheimer's disease. By leveraging advanced computational design and structural insights, Vistella aims to create disease-modifying treatments that prevent or reverse the progression of cognitive decline. The company is a spin-out from the University of California, San Francisco, and is supported by venture capital firms specializing in early-stage life sciences. Vistella's platform focuses on identifying specific strains of misfolded proteins to develop highly targeted interventions. The company is currently advancing its lead programs through discovery and early pre-clinical validation.